Sarepta Therapeutics, Inc. (SRPT) saw its share price trade relatively negative in the recent trading session. The share price was last updated to $29.73 with a loss of -1.33 points or -4.29%. The net money flow was $0.98 million and the up/down ratio was 1.28. Approximately $4.46 million was the inflow in upticks and $3.49 million was the outflow in downticks. On a weekly measure, the shares have seen a price change of -3.57%.The shares witnessed a block transaction with a net money flow of $0.59 million. The total money in uptick was $0.59 million and in downtick was $0 million with the up/down ratio reaching 0.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Sarepta Therapeutics, Inc. has dropped 3.8% in the last five trading days, however, the shares have posted positive gains of 6.09% in the last 4 weeks. Sarepta Therapeutics, Inc. has dropped 25.84% during the last 3-month period . Year-to-Date the stock performance stands at 6.09%. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) witnessed a decline in the market cap on Wednesday as its shares dropped 6.31% or 1.96 points. After the session commenced at $30.51, the stock reached the higher end at $30.8 while it hit a low of $28.58. With the volume soaring to 3,856,852 shares, the last trade was called at $29.1. The company has a 52-week high of $63.73. The company has a market cap of $1,589 million and there are 54,590,380 shares in outstanding. The 52-week low of the share price is $8.
Company has reported several Insider transactions to the SEC, on Oct 19, 2016, Sandesh Mahatme (Senior Vice President, CFO) sold 30,000 shares at 50.08 per share price.On Sep 30, 2016, Shamim Ruff (SVP, Regulatory Affairs & Qual) sold 7,311 shares at 60.00 per share price.On Sep 26, 2016, Edward M. Md Kaye (President, CEO & CMO) sold 40,179 shares at 60.00 per share price.
Sarepta Therapeutics Inc Last issued its quarterly earnings results on Oct 27, 2016. The company reported $-0.95 EPS for the quarter, beating the analyst consensus estimate by $ 0.33. Analyst had a consensus of $-1.28.During the same quarter in the previous year, the company posted $-1.11 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Sarepta Therapeutics Inc was Reiterated by Morgan Stanley on Jan 4, 2017 to Equal-Weight, Lowers Price Target to $ 33 from a previous price target of $53 .Sarepta Therapeutics Inc was Initiated by JP Morgan on Dec 22, 2016 to Overweight, Price Target of the shares are set at $40.Sarepta Therapeutics Inc was Initiated by Goldman to Neutral on Dec 20, 2016. Sarepta Therapeutics Inc was Reiterated by RBC Capital Mkts on Dec 16, 2016 to Outperform, Lowers Price Target to $ 98 from a previous price target of $106 .Sarepta Therapeutics Inc was Reiterated by Jefferies on Dec 14, 2016 to Hold, Lowers Price Target to $ 32 from a previous price target of $46 .
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Companys diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.